Abstract
Lixisenatide is a new drug from the group of GLP-1 receptor agonists available in our market. Based on its pharmacokinetics properties it is included in the group of prandial GLP-1 receptor agonists (similar to exenatide that is administered twice daily) whose action preferentially consists in the reduction of postprandial glycaemia as compared to fasting glycaemia, based on the mechanisms of markedly slowed-down stomach evacuation, reduced glucagon secretion and increased insulin secretion.
These specifics predestine the selection of patients to received lixisenatide. These include patients who typically experience marked increase of glycaemia after meals, with milder impairment of fasting glycaemia, associated comorbidities, and especially those with increased risk of hypoglycaemia.
Its advantage is the administration once daily, prior to the first meal of the day or prior to supper, and good tolerance. It is indicated as part of combinations with oral antidiabetic agents or basal insulin where increased postprandial glycaemia persists.